Literature DB >> 11255454

Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease.

L Ho1, D Purohit, V Haroutunian, J D Luterman, F Willis, J Naslund, J D Buxbaum, R C Mohs, P S Aisen, G M Pasinetti.   

Abstract

BACKGROUND: Prior studies have shown that cyclooxygenase 2 (COX-2), an enzyme involved in inflammatory mechanisms and neuronal activities, is up-regulated in the brain with Alzheimer disease (AD) and may represent a therapeutic target for anti-inflammatory treatments.
OBJECTIVE: To explore COX-2 expression in the brain as a function of clinical progression of early AD. DESIGN AND MAIN OUTCOME MEASURES: Using semiquantitative immunocytochemistry, we analyzed COX-2 protein content in the hippocampal formation in 54 postmortem brain specimens from patients with normal or impaired cognitive status. SETTING AND PATIENTS: Postmortem study of nursing home residents.
RESULTS: The immunointensity of COX-2 signal in the CA3 and CA2 but not CA1 subdivisions of the pyramidal layers of the hippocampal formation of the AD brain increased as the disease progressed from questionable to mild clinical dementia as assessed by Clinical Dementia Rating. COX-2 signal was increased in all 3 regions examined among cases characterized by severe dementia.
CONCLUSION: Neuronal COX-2 content in subsets of hippocampal pyramidal neurons may be an indicator of progression of dementia in early AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11255454     DOI: 10.1001/archneur.58.3.487

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  50 in total

1.  Neuronal overexpression of cyclooxygenase-2 does not alter the neuroinflammatory response during brain innate immune activation.

Authors:  Saba Aid; Nishant Parikh; Sara Palumbo; Francesca Bosetti
Journal:  Neurosci Lett       Date:  2010-05-06       Impact factor: 3.046

Review 2.  Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies.

Authors:  Mahyar Etminan; Sudeep Gill; Ali Samii
Journal:  BMJ       Date:  2003-07-19

3.  Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology.

Authors:  Michal Schnaider Beeri; Jeremy M Silverman; Kenneth L Davis; Deborah Marin; Hillel Z Grossman; James Schmeidler; Dushyant P Purohit; Daniel P Perl; Michael Davidson; Richard C Mohs; Vahram Haroutunian
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-04       Impact factor: 6.053

Review 4.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Anti-inflammatory agents in Alzheimer's disease.

Authors:  Paul S Aisen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 6.  Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.

Authors:  Imrich Blasko; Beatrix Grubeck-Loebenstein
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 7.  Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation.

Authors:  Rituraj Niranjan
Journal:  Mol Neurobiol       Date:  2013-02-19       Impact factor: 5.590

Review 8.  Glial cell dysregulation: a new perspective on Alzheimer disease.

Authors:  Rommy von Bernhardi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

9.  Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease.

Authors:  Daniela L Krause; Norbert Müller
Journal:  Int J Alzheimers Dis       Date:  2010-06-14

10.  Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia.

Authors:  Johannes C M Schlachetzki; Bernd L Fiebich; Elisabeth Haake; Antonio C P de Oliveira; Eduardo Candelario-Jalil; Michael T Heneka; Michael Hüll
Journal:  J Neuroinflammation       Date:  2010-01-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.